| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT07342764 Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A… |
Primary endpoint(s) modified |
| 2026-06-11 | NCT07342764 Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A… |
Trial arms changed: 3 -> 2 |
| 2026-06-10 | NCT07214818 SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome |
overall status: "Active Not Recruiting" → "Recruiting" |
| 2026-06-09 | NCT04699838 Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients… |
date change Primary completion pushed: 2026-03 -> 2026-07 |
| 2026-06-09 | NCT05741658 The Fontan Dapagliflozin Pilot Study |
date change Primary completion pushed: 2026-04 -> 2026-06 |
| 2026-06-06 | NCT05379972 Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers |
Trial completed |
| 2026-06-06 | NCT05379972 Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers |
date change Completion moved earlier: 2028-12 -> 2026-01-22 |
| 2026-06-04 | NCT04753879 Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic… |
date change Primary completion moved earlier: 2026-12-01 -> 2026-07-01 |
| 2026-06-04 | NCT04753879 Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic… |
date change Completion moved earlier: 2029-12-01 -> 2026-07-01 |
| 2026-06-03 | NCT03732820 Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic… |
date change Completion pushed: 2026-04-27 -> 2027-02-05 |
| 2026-05-30 | NCT05411094 Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation… |
date change Completion pushed: 2026-07-01 -> 2028-07-01 |
| 2026-05-30 | NCT05203445 A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC)… |
Enrollment reduced: 23 -> 6 participants |
| 2026-05-30 | NCT05203445 A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC)… |
date change Primary completion moved earlier: 2027-01 -> 2025-05-29 |
| 2026-05-30 | NCT02693535 TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a… |
Trial sites expanded: 174 -> 181 locations |
| 2026-05-29 | NCT05411094 Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation… |
Recruitment suspended |
| 2026-05-29 | NCT05411094 Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation… |
critical why stopped: null → "Other - assessment of dose finding" |
| 2026-05-29 | NCT05411094 Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation… |
date change Completion moved earlier: 2028-07-01 -> 2026-07-01 |
| 2026-05-29 | NCT02893917 Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug… |
date change Completion pushed: 2026-06-18 -> 2027-05-31 |
| 2026-05-28 | NCT06177171 Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated… |
Sponsor changed: Pamela Munster -> Varun Monga, MBBS |
| 2026-05-23 | NCT06966700 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast… |
Trial sites expanded: 287 -> 291 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07641855 A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant… | Phase 2/3 | Not Yet Recruiting |
| 2026-06-03 | NCT07624305 A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With… | Phase 3 | Not Yet Recruiting |
| 2026-06-02 | NCT07621380 Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction | Phase 4 | Not Yet Recruiting |
| 2026-05-29 | NCT07614230 SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue… | Phase 4 | Recruiting |
| 2026-05-27 | NCT07610174 Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients… | Phase 2 | Completed |
| 2026-05-19 | NCT07595289 DP-DCT 1.0：A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM… | Not Yet Recruiting | |
| 2026-05-15 | NCT07589075 Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in… | Phase 4 | Completed |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06785116 | A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk… | Gestational Hypertension | Recruiting |
| NCT06364930 | SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus | Chronic Hepatitis B | Recruiting |
| NCT05390892 | PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Type2Diabetes | Recruiting |
| NCT07405216 | Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With… | Chronic Kidney Disease (Mild to Moderate) | Recruiting |
| NCT06560801 | Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney… | Chronic Kidney Diseases | Recruiting |
| NCT07614230 | SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue… | Type 2 Diabetes Mellitus (T2DM) | Recruiting |
| NCT06291155 | Mechanism of SGLT2 Inhibition in the Kidney | Type 2 Diabetes | Recruiting |
| NCT07351643 | CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients… | ACS (Acute Coronary Syndrome) | Not Yet Recruiting |
| NCT06610526 | A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease | Chronic Kidney Disease | Active, Not Recruiting |
| NCT06851962 | Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. | Diabetes Mellitus Type 2 | Active, Not Recruiting |
| NCT05309785 | Safety and Efficacy of Canagliflozin in Advanced CKD | ESRD | Active, Not Recruiting |
| NCT06858436 | SGLT2 Inhibitor Utilization Re-perfusion Therapy | Acute Ischemic Stroke From Large Vessel Occlusion | Not Yet Recruiting |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With… | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting |
| NCT07537088 | Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone… | T2DM (Type 2 Diabetes Mellitus) | Not Yet Recruiting |
| NCT07527390 | CANagliflozin In DIALysis Patients | Dialysis | Not Yet Recruiting |
| NCT07547878 | Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | Chronic Kidney Disease | Not Yet Recruiting |
| NCT07621380 | Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction | Type 2 Diabetes Mellitus Myocardial Infarction | Not Yet Recruiting |
| NCT05741658 | The Fontan Dapagliflozin Pilot Study | Heart Failure | Enrolling by Invitation |
| NCT07342764 | Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A… | Antipsychotic-induced Weight Gain (AIWG) | Not Yet Recruiting |
| Phase 3 | |||
| NCT07297589 | Epicardial Cardiac Fat-CT (EPIC-CT) | STEMI - ST Elevation Myocardial Infarction | Recruiting |
| NCT07295223 | Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and… | Acute Myocardial Infarction With ST Elevation | Recruiting |
| NCT06712472 | Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant… | Endometrial Cancer | Recruiting |
| NCT06174753 | Dapagliflozin in STEMI | ST Elevation Myocardial Infarction | Recruiting |
| NCT07025629 | Dapagliflozin for Cardio-renal Protection After ICU Discharge | Heart Failure and Chronic Kidney Disease Post-ICU | Recruiting |
| NCT06580314 | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian… | Fallopian Tube Endometrioid Adenocarcinoma | Recruiting |